Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

RSV Vaccines Topic Center

Featured Article

Quiz
Estimated Fatality Rate of RSV in Older Adults
08/28/2023
Among adults aged 60 years or older, what is the estimated fatality rate of RSV?
Among adults aged 60 years or older, what is the estimated fatality rate of RSV?
Among adults aged 60 years or...
08/28/2023
First Report Managed Care
News
RSV Vaccine Combo Shows Promise for Enhanced Protection
08/22/2023
Jolynn Tumolo
According to recent research, including recombinant RSV prefusion conformation-stabilized fusion protein in the vaccine improved the overall effectiveness in generating immune reactions in older patients.
According to recent research, including recombinant RSV prefusion conformation-stabilized fusion protein in the vaccine improved the overall effectiveness in generating immune reactions in older patients.
According to recent research,...
08/22/2023
First Report Managed Care
Quiz
Testing Results of the Bivalent RSV Prefusion F Vaccine
08/14/2023
What has NOT been found as a result of administering the bivalent RSV prefusion F vaccine in older adults?
What has NOT been found as a result of administering the bivalent RSV prefusion F vaccine in older adults?
What has NOT been found as a...
08/14/2023
First Report Managed Care
News
RSV Prefusion F Vaccine Prevents RSV Illness in Older Adults
08/10/2023
Jolynn Tumolo
Recent clinical trial findings indicate that the RSVpreF vaccine demonstrated efficacy in preventing RSV-associated respiratory illnesses in older adults with no significant safety concerns.
Recent clinical trial findings indicate that the RSVpreF vaccine demonstrated efficacy in preventing RSV-associated respiratory illnesses in older adults with no significant safety concerns.
Recent clinical trial findings...
08/10/2023
First Report Managed Care
Quiz
RSV Vaccine Potential Economic Savings
07/26/2023
Researchers suggest an RSV vaccine with coverage and efficacy similar to influenza vaccination could save the US economy how much money in direct medical costs per RSV season?
Researchers suggest an RSV vaccine with coverage and efficacy similar to influenza vaccination could save the US economy how much money in direct medical costs per RSV season?
Researchers suggest an RSV...
07/26/2023
First Report Managed Care
News
RSV Vaccination in US Older Adults Could Save Up to $1 Billion Per Season
07/24/2023
Jolynn Tumolo
"Our analysis provides contemporary estimates of the population-level RSV disease burden and insights into the economic value drivers for RSV vaccination," said researchers. 
"Our analysis provides contemporary estimates of the population-level RSV disease burden and insights into the economic value drivers for RSV vaccination," said researchers. 
"Our analysis provides...
07/24/2023
First Report Managed Care
Quiz
Key Features of RSV mRNA Vaccine Development
07/21/2023
What is a key feature of the RSV mRNA vaccine that must be accounted for in the vaccine development process? 
What is a key feature of the RSV mRNA vaccine that must be accounted for in the vaccine development process? 
What is a key feature of the RSV...
07/21/2023
First Report Managed Care
News
Cell-Based Relative Potency Assay Assessed for RSV Vaccine Development
07/19/2023
Julie Gould
Researchers tested RSV mRNA vaccine V171 through a relative potency assay to assess its ability to induce humoral and cellular immunity responses. 
Researchers tested RSV mRNA vaccine V171 through a relative potency assay to assess its ability to induce humoral and cellular immunity responses. 
Researchers tested RSV mRNA...
07/19/2023
First Report Managed Care
News
Trial Finds Lower Viral Load, Symptom Scores With MVA-BN-RSV Vaccine
06/27/2023
Jolynn Tumolo
The findings of a phase 2a trial show the MVA-BN-RSV vaccine reduced respiratory syncytial virus load, symptoms, and infections while eliciting immune responses.
The findings of a phase 2a trial show the MVA-BN-RSV vaccine reduced respiratory syncytial virus load, symptoms, and infections while eliciting immune responses.
The findings of a phase 2a trial...
06/27/2023
First Report Managed Care
News
Mapping the Diversity and Evolution of RSV T Cell Epitopes for Vaccine Design
06/26/2023
Julie Gould
Human respiratory syncytial virus (RSV) strains cluster into distinct groups based on T cell epitope profiles, indicating divergent immunogenic profiles and highlighting the need for different vaccine strategies for RSV-A and RSV-B groups.
Human respiratory syncytial virus (RSV) strains cluster into distinct groups based on T cell epitope profiles, indicating divergent immunogenic profiles and highlighting the need for different vaccine strategies for RSV-A and RSV-B groups.
Human respiratory syncytial...
06/26/2023
First Report Managed Care
Quiz
RSV Vaccine Eligibility
06/21/2023
What patient demographic can now receive the FDA-approved RSV vaccine Arexvy?
What patient demographic can now receive the FDA-approved RSV vaccine Arexvy?
What patient demographic can now...
06/21/2023
First Report Managed Care

Newsfeed

Quiz
Estimated Fatality Rate of RSV in Older Adults
08/28/2023
Among adults aged 60 years or older, what is the estimated fatality rate of RSV?
Among adults aged 60 years or older, what is the estimated fatality rate of RSV?
Among adults aged 60 years or...
08/28/2023
First Report Managed Care
News
RSV Vaccine Combo Shows Promise for Enhanced Protection
08/22/2023
Jolynn Tumolo
According to recent research, including recombinant RSV prefusion conformation-stabilized fusion protein in the vaccine improved the overall effectiveness in generating immune reactions in older patients.
According to recent research, including recombinant RSV prefusion conformation-stabilized fusion protein in the vaccine improved the overall effectiveness in generating immune reactions in older patients.
According to recent research,...
08/22/2023
First Report Managed Care
Quiz
Testing Results of the Bivalent RSV Prefusion F Vaccine
08/14/2023
What has NOT been found as a result of administering the bivalent RSV prefusion F vaccine in older adults?
What has NOT been found as a result of administering the bivalent RSV prefusion F vaccine in older adults?
What has NOT been found as a...
08/14/2023
First Report Managed Care
News
RSV Prefusion F Vaccine Prevents RSV Illness in Older Adults
08/10/2023
Jolynn Tumolo
Recent clinical trial findings indicate that the RSVpreF vaccine demonstrated efficacy in preventing RSV-associated respiratory illnesses in older adults with no significant safety concerns.
Recent clinical trial findings indicate that the RSVpreF vaccine demonstrated efficacy in preventing RSV-associated respiratory illnesses in older adults with no significant safety concerns.
Recent clinical trial findings...
08/10/2023
First Report Managed Care
Quiz
RSV Vaccine Potential Economic Savings
07/26/2023
Researchers suggest an RSV vaccine with coverage and efficacy similar to influenza vaccination could save the US economy how much money in direct medical costs per RSV season?
Researchers suggest an RSV vaccine with coverage and efficacy similar to influenza vaccination could save the US economy how much money in direct medical costs per RSV season?
Researchers suggest an RSV...
07/26/2023
First Report Managed Care
News
RSV Vaccination in US Older Adults Could Save Up to $1 Billion Per Season
07/24/2023
Jolynn Tumolo
"Our analysis provides contemporary estimates of the population-level RSV disease burden and insights into the economic value drivers for RSV vaccination," said researchers. 
"Our analysis provides contemporary estimates of the population-level RSV disease burden and insights into the economic value drivers for RSV vaccination," said researchers. 
"Our analysis provides...
07/24/2023
First Report Managed Care
Quiz
Key Features of RSV mRNA Vaccine Development
07/21/2023
What is a key feature of the RSV mRNA vaccine that must be accounted for in the vaccine development process? 
What is a key feature of the RSV mRNA vaccine that must be accounted for in the vaccine development process? 
What is a key feature of the RSV...
07/21/2023
First Report Managed Care
News
Cell-Based Relative Potency Assay Assessed for RSV Vaccine Development
07/19/2023
Julie Gould
Researchers tested RSV mRNA vaccine V171 through a relative potency assay to assess its ability to induce humoral and cellular immunity responses. 
Researchers tested RSV mRNA vaccine V171 through a relative potency assay to assess its ability to induce humoral and cellular immunity responses. 
Researchers tested RSV mRNA...
07/19/2023
First Report Managed Care
News
Trial Finds Lower Viral Load, Symptom Scores With MVA-BN-RSV Vaccine
06/27/2023
Jolynn Tumolo
The findings of a phase 2a trial show the MVA-BN-RSV vaccine reduced respiratory syncytial virus load, symptoms, and infections while eliciting immune responses.
The findings of a phase 2a trial show the MVA-BN-RSV vaccine reduced respiratory syncytial virus load, symptoms, and infections while eliciting immune responses.
The findings of a phase 2a trial...
06/27/2023
First Report Managed Care
News
Mapping the Diversity and Evolution of RSV T Cell Epitopes for Vaccine Design
06/26/2023
Julie Gould
Human respiratory syncytial virus (RSV) strains cluster into distinct groups based on T cell epitope profiles, indicating divergent immunogenic profiles and highlighting the need for different vaccine strategies for RSV-A and RSV-B groups.
Human respiratory syncytial virus (RSV) strains cluster into distinct groups based on T cell epitope profiles, indicating divergent immunogenic profiles and highlighting the need for different vaccine strategies for RSV-A and RSV-B groups.
Human respiratory syncytial...
06/26/2023
First Report Managed Care
John Hoffman
Conference Coverage
Strategies for Infusion Providers to Advance Health Equity
06/28/2024
Explore the distinctions between health equity and DE&I, understand the impact of market influences on patient care outcomes, and discover practical strategies to enhance patient support in this interview with NICA 2024 session speaker John...
Explore the distinctions between health equity and DE&I, understand the impact of market influences on patient care outcomes, and discover practical strategies to enhance patient support in this interview with NICA 2024 session speaker John...
Explore the distinctions between...
06/28/2024
First Report Managed Care
News
Johnson & Johnson Expands Use of Prezcobix for Pediatric Patients in the US
06/21/2024
Johnson & Johnson aims to expand use of its HIV-1 therapy, Prezcobix, for younger patients in the US, potentially paving the way for improved treatment options for pediatric patients with the virus.
Johnson & Johnson aims to expand use of its HIV-1 therapy, Prezcobix, for younger patients in the US, potentially paving the way for improved treatment options for pediatric patients with the virus.
Johnson & Johnson aims to expand...
06/21/2024
First Report Managed Care
News
HAVEN 7 Trial Evaluates Emicizumab Prophylaxis in Infants With Hemophilia A
06/19/2024
Grace Taylor, MS, MA
A study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab in infants from birth to age ≤12 months who have hemophilia A without factor VIII inhibitors.
A study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab in infants from birth to age ≤12 months who have hemophilia A without factor VIII inhibitors.
A study evaluated the efficacy,...
06/19/2024
First Report Managed Care
News
MS Disease-Modifying Treatments Affect Cellular Response to Epstein-Barr Virus Antigen
06/14/2024
Jolynn Tumolo
Testing cellular response to Epstein-Barr virus nuclear antigen-1 (EBNA-1) may benefit patients with multiple sclerosis (MS), suggests a study published in the journal Neurology: Neuroimmunology & Neuroinflammation.
Testing cellular response to Epstein-Barr virus nuclear antigen-1 (EBNA-1) may benefit patients with multiple sclerosis (MS), suggests a study published in the journal Neurology: Neuroimmunology & Neuroinflammation.
Testing cellular response to...
06/14/2024
First Report Managed Care
News
Comparing Rural and Urban HIV Risk Behaviors Among Adolescent Sexual Minority Males
06/11/2024
Hannah Musick
Research highlights differing HIV risk behaviors and service use between urban and rural adolescent sexual minority males in the US, emphasizing the need for targeted interventions to reduce infection rates in rural areas where access to...
Research highlights differing HIV risk behaviors and service use between urban and rural adolescent sexual minority males in the US, emphasizing the need for targeted interventions to reduce infection rates in rural areas where access to...
Research highlights differing...
06/11/2024
First Report Managed Care
News
Fitusiran Prophylaxis Shows Promise for Protection Against Bleeding for Patients With Hemophilia A or B
06/05/2024
Grace Taylor, MS, MA
A phase 3 study evaluated the efficacy and safety of fitusiran in males with hemophilia A or B who were receiving bypassing agent (BPA)/clotting factor concentrate (CFC) prophylaxis.
A phase 3 study evaluated the efficacy and safety of fitusiran in males with hemophilia A or B who were receiving bypassing agent (BPA)/clotting factor concentrate (CFC) prophylaxis.
A phase 3 study evaluated the...
06/05/2024
First Report Managed Care
Conference Coverage
Administrative Health Claims Data Study Highlights Demographics of Patients With Multiple Sclerosis in the US
05/31/2024
Grace Taylor, MS, MA
A new study highlights demographic data on subpopulations of people with multiple sclerosis (MS) in the US based on findings from administrative health claims (AHC) data sets.
A new study highlights demographic data on subpopulations of people with multiple sclerosis (MS) in the US based on findings from administrative health claims (AHC) data sets.
A new study highlights...
05/31/2024
First Report Managed Care
Conference Coverage
Improvements in Patient-Reported Outcomes for Patients With MS Switching to Diroximel Fumarate
05/31/2024
Hannah Musick
This study aims to characterize patient-reported outcomes in individuals with multiple sclerosis (MS) who switched to diroximel fumarate (DRF), showing promising results in symptom severity and disability after 1 year of treatment.
This study aims to characterize patient-reported outcomes in individuals with multiple sclerosis (MS) who switched to diroximel fumarate (DRF), showing promising results in symptom severity and disability after 1 year of treatment.
This study aims to characterize...
05/31/2024
First Report Managed Care
News
Patient Diagnosed With Clinically Isolated Syndrome After Traumatic Brain Injury: Case Study
05/30/2024
Grace Taylor, MS, MA
Researchers presented a case study of a 71-year-old White man who was diagnosed with clinically isolated syndrome (CIS) after experiencing a traumatic brain injury.
Researchers presented a case study of a 71-year-old White man who was diagnosed with clinically isolated syndrome (CIS) after experiencing a traumatic brain injury.
Researchers presented a case...
05/30/2024
First Report Managed Care
News
Increased Understanding of Rosacea Pathogenesis Leads to An Increase in Therapeutic Options
05/30/2024
Lisa Kuhns, PhD
Rosacea imposes a substantial burden on both patients and the economy, and further research is needed to better understand its pathogenesis and develop new treatments, according to an article published in Frontiers in Medicine.
Rosacea imposes a substantial burden on both patients and the economy, and further research is needed to better understand its pathogenesis and develop new treatments, according to an article published in Frontiers in Medicine.
Rosacea imposes a substantial...
05/30/2024
First Report Managed Care

Advertisement

Advertisement

FRMC Volume 21, Issue 2

Current Issue

June 2024
Volume 21
Issue 2
Current Issue
Issue Archive

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement